Completion of the Human Papillomavirus Vaccination Series Among Adolescent Users and Nonusers of School-Based Health Centers.
CONCLUSION: Adolescent SBHC users had higher odds of completing the HPV vaccine series than adolescents who received all doses in traditional health care settings. SBHCs should be leveraged to increase adolescent immunization rates. PMID: 31404508 [PubMed - as supplied by publisher]
Evidence suggests that the inflammatory bowel disease (IBD) patients may have an elevated risk of Human papillomavirus (HPV)-associated cancers when compared with those without IBD. HPV vaccination has been recommended for 11 to 26 years old males and females. Recently, the Centers for Disease Control and Prevention (CDC) has updated the guideline to include adults aged 27 to 45 who are not adequately vaccinated. To the best of our knowledge, population-level HPV vaccine uptake rates among patients with IBD remains unknown.
From 2013 to 2016, negative information about the HPV (human papillomavirus) vaccine spread widely through Danish media outlets. As a result, thousands of girls did not receive the vaccine.
CONCLUSIONS:The authors found relatively higher and increasing incidence rate of OPC in Florida and lower rate of HPV vaccination among adolescents in Florida than in the nation overall.PRACTICAL IMPLICATIONS:The trends illustrated may stimulate policy changes to increase HPV vaccination for children and enhance the understanding of its benefits.
Publication date: Available online 21 January 2020Source: The LancetAuthor(s): Maria Brotons, Laia Bruni
Publication date: Available online 21 January 2020Source: The LancetAuthor(s): Mélanie Drolet, Marc Brisson
Publication date: Available online 21 January 2020Source: The LancetAuthor(s): Peter Sasieni, Jack Cuzick
Cancer-causing HPV16 and 18 infections are now extremely uncommon in young sexually active women in England, following the introduction of HPV (human papillomavirus) vaccination in 2008.
Abstract We conducted a critical appraisal of published Phase 2 and 3 efficacy trials in relation to the prevention of cervical cancer in women. Our analysis shows the trials themselves generated significant uncertainties undermining claims of efficacy in these data. There were 12 randomised control trials (RCTs) of Cervarix and Gardasil. The trial populations did not reflect vaccination target groups due to differences in age and restrictive trial inclusion criteria. The use of composite and distant surrogate outcomes makes it impossible to determine effects on clinically significant outcomes. It is still uncerta...